Bristol Myers Squibb (CELG-RI) Tax Provisions (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Tax Provisions for 18 consecutive years, with $770.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Tax Provisions rose 67.39% year-over-year to $770.0 million; the TTM figure through Jun 2026 stood at $2.6 billion (up 72.27% YoY), while the FY2025 annual figure was $2.3 billion, up 310.11% from the prior year.
• Tax Provisions rose to $770.0 million in Q2 2026 per CELG-RI's latest filing, from $561.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $919.0 million in Q3 2025 and bottomed at -$398.0 million in Q2 2024.
• Historically, Tax Provisions has averaged $329.2 million across 5 years, with a median of $432.0 million in 2022.
• Annual changes were most pronounced in 2023 — Tax Provisions tumbled 141.21% — and 2025, when it surged 287.88%.
• Bristol Myers Squibb's Tax Provisions stood at -$166.0 million in 2022, then soared by 46.99% to -$88.0 million in 2023, then soared by 212.5% to $99.0 million in 2024, then soared by 287.88% to $384.0 million in 2025, then surged by 100.52% to $770.0 million in 2026.
• Business Quant data shows CELG-RI's Tax Provisions at $770.0 million in Q2 2026, $561.0 million in Q1 2026, and $384.0 million in Q4 2025.